Table 2.
5-Year OS (95% CI) | MST (Months) (95% CI) | p-Value | ||||
---|---|---|---|---|---|---|
Male | Female | Male | Female | Log-Rank | Generalized Wilcoxon | |
Overall | 52.6 (51.7–53.5) | 55.3 (53.9–56.7) | 69 (65.2–72.8) | 86 (76.4–95.6) | 0.0018 | 0.756 |
Pathology Classification | ||||||
Differentiated | 60.7 (59.6–61.9) | 64.2 (62.3–66.2) | 97 (91.6–102.4) | 126 (114.1–137.9) | 0.0025 | 0.097 |
Undifferentiated | 37.3 (35.6–39.1) | 48.5 (46.3–50.7) | 27 (24.6–29.3) | 53 (40.6–65.4) | <0.001 | <0.001 |
Clinical Stage | ||||||
Localized without LNM | 76.3 (75.2–77.4) | 81.7 (80.2–83.3) | 142 (–) | – | <0.001 | <0.001 |
Localized with LNM | 51.81 (49.0–54.8) | 58.88 (54.6–63.6) | 65 (56.6–73.4) | 111 (78.5–143.5) | 0.0026 | 0.084 |
Adjacent organ invasion | 29.68 (27.2–32.4) | 31.6 (28.1–35.6) | 26 (23.8–28.2) | 25 (22.0–27.9) | 0.55 | 0.433 |
Distant metastasis | 4.45 (3.59–5.51) | 5.23 (3.85–7.11) | 7 (6.5–7.5) | 6 (5.3–6.7) | 0.179 | 0.006 |
OS: overall survival; MST: Median survival time.